Global epidemiology and burden of HCV infection and HCV-related disease (Q30240220)

12 June 2017

1 reference

title

Global epidemiology and burden of HCV infection and HCV-related disease (English)

1 reference

12 June 2017

1 reference

2

Hashem B El-Serag

1 reference

12 June 2017

3

Fasiha Kanwal

1 reference

12 June 2017

1

Aaron P Thrift

1 reference

PubMed ID

27924080

12 June 2017

language of work or name

English

0 references

publication date

7 December 2016

1 reference

Nature Reviews Gastroenterology & Hepatology

12 June 2017

1 reference

12 June 2017

14

1 reference

12 June 2017

2

1 reference

12 June 2017

122-132

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

12 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Case control study to identify risk factors for acute hepatitis C virus infection in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The global burden of disease attributable to contaminated injections given in health care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Curing hepatitis C with pills: a step toward global control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Viral hepatitis and the Global Burden of Disease: a need to regroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Progression to cirrhosis in hepatitis C patients: an age-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The impact of hepatitis C burden: an evidence-based approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

HCV-associated liver cancer without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Association between chronic hepatitis C infection and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Epidemiology of viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Extrahepatic manifestations of hepatitis C among United States male veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Extrahepatic manifestations of chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Development of squamous cell carcinoma in hepatitis C virus-associated lichen planus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Oral diseases associated with hepatitis C virus infection. Part 2: lichen planus and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Oral manifestations of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Detection of hepatitis C virus RNA in oral lichen planus and oral cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Chronic hepatitis C infection as a risk factor for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk for renal cell carcinoma in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C virus infection and risk of cancer: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Extrahepatic manifestations of hepatitis C infection: navigating CHASM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Cryoglobulinemia Vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Therapy for hepatitis C virus-related cryoglobulinemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk factors for cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

The changing burden of hepatitis C virus infection in the United States: model-based predictions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Medical procedures and the risk of iatrogenic hepatitis C infection: case-controlled study in north-eastern Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Outcome of hepatitis C infection: bleak or benign?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.176

31 March 2020

1 reference

12 December 2020

Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy

1 reference

12 December 2020

Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy

1 reference

12 December 2020

Biological agents. Volume 100 B. A review of human carcinogens

1 reference

12 December 2020

Natural course of chronic hepatitis C

1 reference

12 December 2020

10.1038/NRGASTRO.2016.176

Identifiers

DOI

1 reference

PubMed ID

27924080

Dimensions Publication ID

12 June 2017

0 references

1 reference

PubMed ID

27924080